-+ 0.00%
-+ 0.00%
-+ 0.00%

Acurx DNA pol IIIC inhibitors spare gut microbiome in MRSA mouse study, poster shows

PUBT·05/04/2026 12:01:45
Listen to the news
Acurx DNA pol IIIC inhibitors spare gut microbiome in MRSA mouse study, poster shows
  • Acurx Pharmaceuticals announced microbiome data on its preclinical DNA pol IIIC inhibitor antibiotics were presented in a scientific poster at ESCMID Global 2026 in Munich, held April 17-21.
  • In a mouse MRSA infection model, the compounds showed systemic antibacterial activity while preserving gut microbiome diversity and baseline-like community structure, contrasting with linezolid.
  • The results support a potential class effect that could differentiate the program by aiming to treat serious Gram-positive infections while reducing risk of antibiotic-driven dysbiosis.
  • Acurx said its DNA pol IIIC inhibitor candidates are positioned for FDA QIDP and Fast-Track eligibility, signaling a regulatory pathway aimed at accelerating development for high-need infections.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.